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Azathioprine is an immunosuppressant and cytotoxic pro-drug which acts to impair purine
synthesis. Side effects including nausea, rash, hepatotoxicity and bone marrow suppression
frequently limit its use. Thiopurine S-methyl transferase (TPMT) is an important enzyme which
metabolises thiopurines such as azathioprine to inactive metabolites. TPMT activity varies
greatly between individuals, and has a trimodal distribution. Individuals may be homozygous
for the highly active wild type allele, heterozygous with a low activity variant allele, or be
homozygous for the low activity variant. Reduced TPMT activity conveys a greater risk of drug
related side effects from thiopurines.
We report a case in which azathioprine used to treat non specific interstitial pneumonia re-
sulted in marked pancytopaenia. Azathioprine treatment had been commenced without first
checking the TPMT status. The subsequent discovery of TPMT deficiency in this patient ex-
plained the development of complications. Limited therapeutic options led to the patient
being treated with an extremely low azathioprine dose regime. The drug was tolerated without
further toxicity.
This case highlights the benefits of screening the TPMT activity of all patients where azathi-
oprine treatment is being considered. It also gives further evidence that TPMT deficient indi-
viduals are able to tolerate a very low dose azathioprine regime without side effects.
ª 2008 Elsevier Ltd. All rights reserved.0) 121 4242746; fax: þ44 (0)
@heartofengland.nhs.uk
ll rights reserved.Statement of clinical relevance/originality
This case report relates to the development of side effects
following the use of azathioprine in a Thiopurine S-methyl
transferase (TPMT) deficient individual. This is a topic of
Figure 1 High resolution CT scans of the thorax before and after 18 months of treatment. A widespread reticular patterning,
patchy ground glass opacification, and traction bronchiectasis are evident on the first scan. There has been almost complete
resolution of these changes following steroid and immunosuppressive therapy.
Azathioprine in TPMT deficiency 103much interest currently as there is no consensus as
to whether routine testing of TPMT is appropriate prior to
commencing azathioprine therapy. This report speaks to
that debate by highlighting the complications which can
develop in TPMT deficient individuals. In addition this
case adds to the very small number of reports in the liter-
ature where low dose azathioprine has been used in
TPMT deficient individuals without the development of
toxicity.
Case report
A 68-year old Caucasian woman presented with a three
week history of progressive shortness of breath on exertion,
a dry cough and general malaise. She was a non-smoker
with no relevant previous medical or family history of
respiratory disease. Positive findings from clinical exami-
nation included basal inspiratory crepitations in both lung
fields.
Bilateral reticularenodular shadowing was seen on the
chest radiograph. High resolution computed tomography of
the thorax demonstrated a fine reticular pattern with
subpleural and basal predominance. Areas of ground glass
shadowing and traction bronchiectasis were also noted
(Fig. 1.) Full lung function tests showed a restrictive defect
with a severe impairment in gas transfer (Table 1). Bron-
choscopy and lavage was performed, but no atypical cells
were seen or infectious agents cultured. Lavage fluid
comprised 53% polymorphs, 24% lymphocytes, 21%Table 1 Serial lung function results showing marked improve
expiratory volume in one second, DLCO Diffusion capacity of the
Length
of time
treated
Baseline One
month
Two
months
FVC 1.48 1.73 1.7
% Pred 62 72 71
FEV1 1.23 1.54 1.58
% Pred 62 78 80
DLCO 0.93 1.51 1.71
% Pred 13 21 24macrophages, 2% eosinophils. Rheumatoid factor was
positive by latex testing, but Rose Waaler titre was nega-
tive. Antinuclear antibodies, extractable nuclear anti-
bodies, anti-dsDNA, anti-centromere, ANCA, anti-
glomerular basement antibody, and angiotensin converting
enzyme levels were within normal limits. Avian preciptins
were negative (budgerigar, chicken, pigeon) and protein
electrophoresis did not demonstrate paraprotein banding.
There was a polyclonal rise in IgM.
The patient was too unwell for an open lung biopsy, and
a diagnosis of non-specific interstitial pneumonia (NSIP) was
made on the basis of her clinical, lung function, laboratory,
and radiological findings.
Prednisolone 30 mg once daily was commenced with
azathioprine 50 mg twice daily, increased to three times
a day after seven days, leading to significant clinical
improvement. Repeat lung function showed improvement
from baseline (Table 1).
The clinical improvement in the patient’s condition was
maintained over the following month, however blood tests
taken at the end of this period indicated the development
of pancytopaenia (WCC fall from 11.1 to 2.9 109/l, Hb fall
from 12.9 to 8.7 g/dl.) Treatment with azathioprine was
stopped, after which the blood indices normalised. Lung
function continued to improve over the following five
months on monotherapy with prednisolone (Table 1),
however the gradual development of Cushingoid facies and
body habitus emphasised the need for a steroid sparing
agent.ment with therapy FVC Forced vital capacity, FEV1 Forced
lung for carbon monoxide, % Pred Percentage predicted.
Five
months
Nine
months
One
year
Two
years
1.82 2.00 1.92 2.11
81 89 85 95
1.67 1.76 1.66 1.82
91 95 89 99
2.27 2.89 3.07 3.22
34 43 46 48
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methyl transferase (TPMT) activity was requested and
found to be undetectable at <1 nmol 6-MTG/g Hb/hr.1 The
deficient TPMT activity status of the patient was also
confirmed by TPMT genotyping. The patient was found to
be homozygous for the most common polymorphism asso-
ciated with deficient TPMT enzyme activity in Caucasians,
TPMT*3A, which is characterised by a double mutant allele
(G to A transition at nucleotide 460 on exon 7, and A to G
transition at nucleotide 719 on exon 10.)2,3
A very low dose of azathioprine (5 mg OD) was restarted,
and the steroid dose to be weaned. No significant side
effects were suffered by the patient. Lung function
continued to improve two years out from the initial
presentation (Table 1), and a repeat HRCT showed almost
complete resolution of the previously observed radiological
abnormalities (Fig. 1).Discussion
Azathioprine is a mercaptopurine derivative with both
cytotoxic and immunosuppressive effects. Indications for
its use are found across many medical specialties, and
include rheumatoid arthritis, inflammatory bowel disease,
vasculitis, chronic hepatitis, a number of dermatological
conditions and the prevention of rejection of solid organ
transplants.
The subject of this case report was diagnosed and
treated for NSIP. Whilst many respiratory physicians use
azathioprine in the management of interstitial lung disease
there is limited evidence of its efficacy, even for idiopathic
pulmonary fibrosis (IPF) which is the most common and well
investigated of these conditions.4,5 Of the few good quality
studies in this area, a randomised controlled trial
comparing an azathioprine and prednisolone combination
with prednisolone alone in 27 patients with IPF demon-
strated a small but statistically significant improvement in
survival for the combination therapy group when adjusted
for age.6
Side effects are common with azathioprine and include
nausea, vomiting, rash, hepatotoxicity, and myelosup-
pression. Severe toxicity has been recorded in 30e42% of
patients treated with the drug.7,8 International guidelines
recommend a cautious approach to azathioprine treat-
ment, using small increments from a low initial dose.9 The
relatively high starting dose in our patient may have
contributed to the development of side effects.
The desire to identify patients at particular risk of drug
related complications following the use of azathioprine led
to the introduction of TPMT testing to the UK in the early
1990s. TPMT is one of the principal enzymes involved in the
metabolism of thiopurines such as azathioprine to inactive
metabolites There is a marked variation in the activity of
TPMT between individuals, largely as a result of single
nucleotide polymorphisms, many of which result in a loss of
enzyme activity compared to the wild type. A trimodal
distribution in enzyme activity has been described which
corresponds to homozygosity for a highly active allele,
heterozygosity with a low activity allele, and homozygosity
for the low activity variant. Thus normal/high levels of
activity are seen in approximately ninety percent of thepopulation, whilst ten percent have low TPMT activity, and
one in three hundred has severely deficient TPMT
activity.10,11 Low levels of TPMT are strongly associated
with marked toxicity secondary to azathioprine.12,13
However, individuals known to have low TPMT activity can
subsequently have their azathioprine dose adjusted,
allowing continuing treatment without acute dose limiting
toxicity. Particular caution is necessary in treating individ-
uals in the severely TPMT deficient group such as the
subject of this case report, although successful use of very
low doses of azathioprine has previously been described in
both inflammatory bowel disease14,15 and acute lympho-
blastic leukaemia.13,16,17 Conversely, patients with partic-
ularly high TPMT activity may require higher than usual
azathioprine doses.
Current guidelines from different specialty professional
bodies vary greatly in whether to recommend routine TPMT
testing prior to the use of azathioprine.18e20 These differ-
ences reflect the lack of evidence at present as to whether
routine pre-treatment TPMT testing will actually reduce
the number of adverse reactions in practice.
This case highlights the problems that can develop when
a patient with TPMT deficient status is treated with stan-
dard azathioprine doses, and the benefits which would be
gained from TPMT testing. Checking TPMT status is
becoming increasingly common practice and can both
ensure that we do not normally use thiopurine drugs in
deficient patients and also so that we can reduce the dose
in heterozygote patients. We also give further evidence
that it is possible to treat TPMT deficient patients using
very low doses of azathioprine without side effects.
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